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PERSPECTIVE
Heart failure and healthcare informatics
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As biomedical research expands our armoury of effective, evidence-based therapies, there is a
corresponding need for high-quality implementation science—the study of strategies to inte-
grate and embed research advances into clinical practice [1]. Large-scale collection and analy-
sis of routinely collected healthcare data may facilitate this in three main ways. Firstly,
evaluation of key healthcare metrics can help to identify the areas of practice that differ most
from guideline recommendations. Secondly, with sufficiently granular data, it may be possible
to detect the underlying drivers of deficiencies in practice. Thirdly, longitudinal data collection
should enable us to evaluate large-scale policy initiatives and compare the effectiveness of dif-
fering strategies on process and patient outcomes.
Clinical practice and evidence-based management of heart failure
Heart failure, perhaps more than any other condition, exemplifies the potential for healthcare
informatics to bridge the gap between practice and evidence-based care. The prevalence of
heart failure is already estimated at 1%–2% and is increasing with our ageing population [2].
Indeed, recent work has demonstrated that incident heart failure cases exceed the four most
common causes of cancer combined in the United Kingdom [3]. Moreover, decompensated
heart failure accounts for up to 5% of all acute unscheduled hospital admissions and has the lon-
gest length of stay of any cardiac condition [4–5]. Given the high rates of debilitating symptoms
and death associated with heart failure, this burden to both patients and healthcare systems pro-
vides a moral and financial imperative to ensure optimal delivery of proven therapies. The treat-
ment of chronic heart failure has one of the most robust evidence bases in clinical medicine,
with multiple landmark trials leading to comprehensive guidelines [6–7]. Yet, despite effective
therapies for heart failure being widely available, there is ample evidence to suggest a significant
gap exists between guideline-directed practice and clinical practice [8–10].
Utilising routinely collected healthcare data in heart failure
In PLOS Medicine, Rahimi and colleagues report the results of a longitudinal analysis of diag-
nostic tests, drug prescriptions, and follow-up patterns in 93,000 individuals with heart failure
in the UK [11]. The authors show convincingly that some aspects of care, such as the use of
diagnostic testing and initiation of evidence-based therapies, have improved over time.
Between 2002 and 2014, natriuretic peptide testing was introduced, and the use of echocardi-
ography increased from 17% to 62%. Similarly, the initiation of combination therapy with a
beta blocker and angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor
antagonist increased 3-fold. However, other key elements of care, such as dose titration of
heart failure therapy, remained poor, and only one in five patients were followed up in primary
care, with the rates declining over the study period. A notable strength of the work is the use of
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both primary and secondary care data within a large and relatively undifferentiated popula-
tion. This approach ensures that insights from the study are applicable to a general heart failure
population and reflect overall care provision. By comparing data across a range of demo-
graphic subgroups, the authors hint at factors that may contribute to suboptimal practice.
They note deficiencies in a range of quality indicators for women, older patients, and those of
low socioeconomic status. It is clear how such findings, if sufficiently robust, could be used to
inform future targeted interventions. The study certainly provides us valuable retrospective
insights into two major policy initiatives designed to improve standards in heart failure treat-
ment focused on primary and secondary care [11]. The data show persuasively that both the
‘quality and outcomes framework’, a primary care reporting and incentives scheme, and the
‘national heart failure audit’ initiative, a secondary care reporting programme, changed behav-
iour, but that the outcomes were tied too tightly to specific measures and may have led to unin-
tended consequences. In many respects, it is not surprising that a system designed to reward
initiation of heart failure treatments but not subsequent dose optimisation would generate an
increase in the former and a decline in the latter. Furthermore, there was a paradoxical decline
in the recording of heart failure diagnosis in primary care from 56% to 36%, whereas the diag-
nosis in secondary care increased steadily. It is possible that practices did not register those
patients who would not achieve all management recommendations, in order to maintain high
adherence rates. This is a critical lesson to bear in mind whenever policies are geared to
improve surrogate markers of quality rather than actual clinical outcomes.
Notwithstanding these strengths, the study does have several limitations. Although it is
apparent which components of heart failure care were suboptimal, the data are insufficient in
their granularity to detect the drivers for these deficiencies and to evaluate some of the key
findings. Specifically, the absence of measures of symptom status, heart rate, blood pressure,
left ventricular ejection fraction, comorbidity, and renal function prevent a complete interpre-
tation of the appropriateness of prescribing. Depending on these parameters, initiation or up-
titration of heart failure therapies may not have been indicated or may even have been contra-
indicated. Therefore, the gap between guideline-directed therapy and practice may, in many
cases, reflect optimal individualised therapy and sensible clinical judgement rather than sys-
tematic deficiencies in care. This point is particularly pertinent to the disparities in prescribing
in the elderly, for whom multimorbidity is common. The low rate of follow-up in both primary
and secondary care is difficult to interpret in the absence of information from community
heart failure programmes, which comprise an essential component of heart failure care deliv-
ery. Finally, the insights into the effectiveness of policy initiatives, though interesting, are frus-
tratingly retrospective and in some ways serve mainly to highlight the missed opportunities
over the last decade. Moving forward, it is imperative to build a healthcare data infrastructure
that is dynamic and can provide insights into contemporary clinical practice.
Healthcare informatics for the delivery of optimal patient-centred
care
Our ability to positively impact on current disparities in care are limited because of the absence
of comprehensive and contemporary data from across the spectrum of care settings. Insuffi-
ciently detailed data impede our ability to identify the causes of disparity in care and, crucially,
to determine whether we are providing optimal care on an individualised basis. To successfully
overcome these challenges, we need to collate healthcare data from across both primary and
secondary care settings in real time and use robust methodology to evaluate major changes in
clinical practice or policy decisions [12]. A platform for sharing data between primary and sec-
ondary care that is linked, anonymised, and sufficiently granular to facilitate a meaningful
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evaluation of current practice is required (Fig 1). This approach should be adopted widely in
healthcare systems such as the National Health Service to ensure we are providing the highest
standards of care for all our patients and using resources most effectively.
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